NCT06842056Not yet recruiting
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Multicentric Multinational Observational Study to Describe the Shift in Stage at Diagnosis of Lung Cancer. No Direct Recruitment of Patients or Administration of Study Medication.
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as large increase in community chest radiography referral rates in response to public awareness campaigns, as well as unintentional detections through cardiac CT(computed tomography) angiograms, or screening for coronary disease may help in detecting the disease at earlier curable stages. Availability and increased access to novel therapies increase the likelihood of an early-stage diagnosis aiming for improved survival.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 7 Feb 2025
- Start date
- 1 Apr 2027
- Primary completion date
- 31 Mar 2030
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT06842056
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Apr 2027 to the primary completion date, 31 Mar 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a concomitant cancer at the time of diagnosis of lung cancer, except for nonmetastatic nonmelanoma skin cancers, or in situ or benign neoplasms: a cancer will be considered concomitant if it occurs within 5 years of lung cancer diagnosis.
Other illness
- Patients presenting with recurrent or relapsed lung cancer.
Who the study is looking for
- Adult female and male patients ≥18 years old.
- Confirmed diagnosis of lung cancer (either cytologically or histologically)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.